Meggle Pharma
Meggle Pharma, a prominent player in the pharmaceutical industry, is headquartered in Germany (DE) and operates extensively across Europe and beyond. Founded in the early 20th century, the company has established itself as a leader in the development and manufacturing of high-quality pharmaceutical products, particularly in the areas of injectables and sterile solutions. With a commitment to innovation and quality, Meggle Pharma offers a diverse range of core products, including advanced formulations and contract manufacturing services. Their unique approach to production ensures compliance with stringent regulatory standards, setting them apart in a competitive market. Recognised for their expertise and reliability, Meggle Pharma has achieved significant milestones, solidifying their position as a trusted partner in the healthcare sector. Their dedication to excellence continues to drive their success and reputation within the industry.
DitchCarbon Score
How does Meggle Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Meggle Pharma's score of 4 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Meggle Pharma's reported carbon emissions
In 2022, Meggle Pharma reported total carbon emissions of approximately 2,065,607,150 kg CO2e. This figure includes emissions across all three scopes: Scope 1 emissions were about 107,065,280 kg CO2e, while Scope 2 emissions totalled approximately 10,656,230 kg CO2e. The majority of their emissions, approximately 1,986,769,570 kg CO2e, originated from Scope 3, which encompasses indirect emissions from sources such as purchased goods and services. Comparatively, in 2018, Meggle Pharma's total emissions were about 1,482,217,100 kg CO2e, with Scope 1 emissions at approximately 87,767,200 kg CO2e, Scope 2 at about 1,135,300 kg CO2e, and Scope 3 emissions reaching around 1,393,314,600 kg CO2e. This indicates a significant increase in total emissions over the four-year period. Despite the lack of specific reduction targets or initiatives disclosed, Meggle Pharma's emissions intensity metrics for 2022 indicate a GHG emissions intensity of 3,880 kg CO2e per tonne of product sold, and 210 kg CO2e per unit of revenue for Scopes 1 and 2 combined. These figures highlight the company's ongoing challenges in managing its carbon footprint amidst rising emissions. Overall, while Meggle Pharma has not publicly committed to specific reduction targets or climate pledges, the data reflects a critical need for enhanced strategies to address their carbon emissions and align with industry standards for sustainability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2018 | 2022 | |
|---|---|---|
| Scope 1 | 87,767,200 | 000,000,000 |
| Scope 2 | 1,135,300 | 00,000,000 |
| Scope 3 | 1,393,314,600 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Meggle Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
